182 related articles for article (PubMed ID: 37523060)
1. Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters.
Li Y; Tan M; Sun S; Stea E; Pang B
Cell Oncol (Dordr); 2023 Dec; 46(6):1807-1820. PubMed ID: 37523060
[TBL] [Abstract][Full Text] [Related]
2. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
4. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
5. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
6. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
7. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
8. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
9. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.
Vydra N; Toma A; Glowala-Kosinska M; Gogler-Piglowska A; Widlak W
BMC Cancer; 2013 Oct; 13():504. PubMed ID: 24165036
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
13. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L
Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545
[TBL] [Abstract][Full Text] [Related]
14. A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics.
Lee HM; Wright WC; Pan M; Low J; Currier D; Fang J; Singh S; Nance S; Delahunty I; Kim Y; Chapple RH; Zhang Y; Liu X; Steele JA; Qi J; Pruett-Miller SM; Easton J; Chen T; Yang J; Durbin AD; Geeleher P
Nat Commun; 2023 Nov; 14(1):7332. PubMed ID: 37957169
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
Zheng X; Cui D; Xu S; Brabant G; Derwahl M
Int J Oncol; 2010 Aug; 37(2):307-15. PubMed ID: 20596658
[TBL] [Abstract][Full Text] [Related]
16. A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC.
Adorni MP; Galetti M; La Monica S; Incerti M; Ruffoni A; Elviri L; Zanotti I; Papotti B; Cavallo D; Alfieri R; Petronini PG; Bernini F
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674503
[TBL] [Abstract][Full Text] [Related]
17. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
20. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
